APA 6th Edition Šeparović, R., Pavlović, M., Silovski, T., Tečić Vuger, A. i Jurić, A. (2016). Systemic therapy of head and neck carcinoma. Libri Oncologici, 44 (2-3), 45-49. Preuzeto s https://hrcak.srce.hr/177240
MLA 8th Edition Šeparović, Robert, et al. "Systemic therapy of head and neck carcinoma." Libri Oncologici, vol. 44, br. 2-3, 2016, str. 45-49. https://hrcak.srce.hr/177240. Citirano 17.05.2021.
Chicago 17th Edition Šeparović, Robert, Mirjana Pavlović, Tajana Silovski, Ana Tečić Vuger i Andreja Jurić. "Systemic therapy of head and neck carcinoma." Libri Oncologici 44, br. 2-3 (2016): 45-49. https://hrcak.srce.hr/177240
Harvard Šeparović, R., et al. (2016). 'Systemic therapy of head and neck carcinoma', Libri Oncologici, 44(2-3), str. 45-49. Preuzeto s: https://hrcak.srce.hr/177240 (Datum pristupa: 17.05.2021.)
Vancouver Šeparović R, Pavlović M, Silovski T, Tečić Vuger A, Jurić A. Systemic therapy of head and neck carcinoma. Libri Oncologici [Internet]. 2016 [pristupljeno 17.05.2021.];44(2-3):45-49. Dostupno na: https://hrcak.srce.hr/177240
IEEE R. Šeparović, M. Pavlović, T. Silovski, A. Tečić Vuger i A. Jurić, "Systemic therapy of head and neck carcinoma", Libri Oncologici, vol.44, br. 2-3, str. 45-49, 2016. [Online]. Dostupno na: https://hrcak.srce.hr/177240. [Citirano: 17.05.2021.]
Sažetak Systemic therapy of head and neck carcinoma is reserved for locally advanced and metastatic disease. Concomitant use of cisplatin and irradiation is still standard protocol for treatment of locally advanced disease although immunoradiotherapy with cetuximab seems to be a good alternative with similar results. The best option for fi rst-line treatment of advanced or metastatic disease is polychemotherapy with addition of cetuximab in patients in good clinical condition. Limited options are available for second-line therapy mostly due to poor performance status of the patients. HPV-positive tumors make a special subgroup of HNSCC in which targeted therapy plays the most important role.